JP2025517476A5 - - Google Patents
Info
- Publication number
- JP2025517476A5 JP2025517476A5 JP2024569253A JP2024569253A JP2025517476A5 JP 2025517476 A5 JP2025517476 A5 JP 2025517476A5 JP 2024569253 A JP2024569253 A JP 2024569253A JP 2024569253 A JP2024569253 A JP 2024569253A JP 2025517476 A5 JP2025517476 A5 JP 2025517476A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nectin
- immunoconjugate
- antibody fragment
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263345453P | 2022-05-25 | 2022-05-25 | |
| US63/345,453 | 2022-05-25 | ||
| PCT/EP2023/063912 WO2023227660A1 (en) | 2022-05-25 | 2023-05-24 | Nectin-4 binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517476A JP2025517476A (ja) | 2025-06-05 |
| JP2025517476A5 true JP2025517476A5 (https=) | 2026-04-27 |
Family
ID=86710807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024569253A Pending JP2025517476A (ja) | 2022-05-25 | 2023-05-24 | ネクチン－４結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250297004A1 (https=) |
| EP (1) | EP4532020A1 (https=) |
| JP (1) | JP2025517476A (https=) |
| KR (1) | KR20250017209A (https=) |
| CN (1) | CN119233994A (https=) |
| AU (1) | AU2023276860A1 (https=) |
| CA (1) | CA3245954A1 (https=) |
| IL (1) | IL316140A (https=) |
| MX (1) | MX2024014288A (https=) |
| TW (1) | TW202411251A (https=) |
| WO (1) | WO2023227660A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| AU2021213421B2 (en) | 2020-01-31 | 2025-02-06 | Innate Pharma | Treatment of cancer |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| WO2024246547A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| WO2025141316A1 (en) * | 2023-12-27 | 2025-07-03 | Intocell, Inc. | Antibody drug conjugates comprising camptothecin derivatives and uses thereof |
| CN120271715A (zh) * | 2024-01-08 | 2025-07-08 | 上海橙帆医药有限公司 | 抗体及其药物偶联物和用途 |
| CN120383674A (zh) * | 2024-01-26 | 2025-07-29 | 鲁南新时代生物技术有限公司 | 一种Nectin-4抗体及其应用 |
| KR20250177512A (ko) * | 2024-06-14 | 2025-12-24 | 삼성바이오에피스 주식회사 | 신규한 항-넥틴-4 항체 및 이의 용도 |
| WO2025261506A1 (zh) * | 2024-06-21 | 2025-12-26 | 信达生物制药(苏州)有限公司 | 抗Nectin-4抗体以及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| HK1040052B (zh) | 1998-05-22 | 2006-09-15 | 第一制药株式会社 | 药物复合物 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| AU2003240482B2 (en) | 2002-05-30 | 2009-03-12 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| WO2004043880A2 (de) | 2002-11-11 | 2004-05-27 | Basf Aktiengesellschaft | Verfahren zur herstellung von 2-keto-l-gulonsäure-c4-c10-alkylestern |
| JP2006507322A (ja) | 2002-11-14 | 2006-03-02 | シンタルガ・ビーブイ | 多重自己脱離放出スペーサーとして構築されたプロドラッグ |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| SI2270010T1 (sl) | 2004-03-01 | 2012-05-31 | Spirogen Ltd | hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov |
| DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| CN104529711B (zh) | 2007-11-21 | 2020-02-07 | 乔治亚大学研究基金公司 | 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法 |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| ES2751549T3 (es) | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| US20130005678A1 (en) | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| EP3409287B9 (en) | 2010-09-29 | 2021-07-21 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| JP6049642B2 (ja) | 2011-02-15 | 2016-12-21 | イミュノジェン・インコーポレーテッド | 複合体の調製方法 |
| US9764038B2 (en) | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| WO2016053107A1 (en) | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| JP7381478B2 (ja) | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| JP7629902B2 (ja) | 2019-03-19 | 2025-02-14 | パウル・シェラー・インスティトゥート | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
| AU2021213421B2 (en) * | 2020-01-31 | 2025-02-06 | Innate Pharma | Treatment of cancer |
| US20230331867A1 (en) * | 2020-09-04 | 2023-10-19 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
-
2023
- 2023-05-24 CA CA3245954A patent/CA3245954A1/en active Pending
- 2023-05-24 US US18/867,898 patent/US20250297004A1/en active Pending
- 2023-05-24 CN CN202380039589.3A patent/CN119233994A/zh active Pending
- 2023-05-24 KR KR1020247037990A patent/KR20250017209A/ko active Pending
- 2023-05-24 EP EP23729061.4A patent/EP4532020A1/en active Pending
- 2023-05-24 AU AU2023276860A patent/AU2023276860A1/en active Pending
- 2023-05-24 WO PCT/EP2023/063912 patent/WO2023227660A1/en not_active Ceased
- 2023-05-24 JP JP2024569253A patent/JP2025517476A/ja active Pending
- 2023-05-24 IL IL316140A patent/IL316140A/en unknown
- 2023-05-25 TW TW112119460A patent/TW202411251A/zh unknown
-
2024
- 2024-11-19 MX MX2024014288A patent/MX2024014288A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025517476A5 (https=) | ||
| KR102923527B1 (ko) | 생체활성 분자 접합체, 이의 제조 방법 및 용도 | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| ES2804614T3 (es) | Conjugados de polipéptidos manipulados usando transglutaminasa | |
| AU2020338481B2 (en) | Targeted dendrimer conjugates | |
| JP2016521256A (ja) | 生物活性分子、そのコンジュゲート、及び治療用途 | |
| CN106795203A (zh) | 用于抗体药物缀合物的稳定性调节接头 | |
| CN106661123A (zh) | 抗‑cd22抗体‑药物缀合物及其使用方法 | |
| BR112021010364A2 (pt) | Composições farmacêuticas que compreendem conjugados de anticorpo-fármaco anti-191p4d12 e métodos de uso das mesmas | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| WO2017196764A1 (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses | |
| JP2025535447A (ja) | 抗体－薬物コンジュゲート、その調製方法および使用 | |
| JPWO2023083846A5 (https=) | ||
| KR20250084935A (ko) | 링커-페이로드 화합물, 접합체 및 이의 응용 분야 | |
| US20240269313A1 (en) | Conjugates comprising a phosphorus(v) moiety and a drug | |
| US20250127916A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| US20250195675A1 (en) | New antibody-drug conjugate as well as methods of production and uses thereof | |
| WO2026018064A1 (en) | Multispecific multi-drug antibody-drug conjugates | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| KR20250148459A (ko) | 항-cntn4 항체를 포함하는 컨쥬게이트 및 이의 용도 |